<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="int-interactant" /><meta name="keywords" content="" /><title>Nortriptyline: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="41001i249.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="41001i249.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=41001i249.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="41001.htm">Appendix 1 Interactions</a> &gt; <a href="53178.htm">List of drug interactions</a> &gt; <a href="41001i229.htm">Antidepressants</a> &gt; <a href="41001i241.htm">Antidepressants, Tricyclic</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="41001i248.htm" title="Previous: Lofepramine">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="41001i251.htm" title="Next: Trimipramine">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_41001i249">Nortriptyline</h1><div id="pC" class="jN"><p class="int-specific-drug-name"><b>Nortriptyline</b>
          has the following interaction information:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>metabolism of  nortriptyline inhibited by cimetidine (increased plasma concentration)</td><td></td></tr></tbody></table><p>Nortriptyline belongs to <b>Antidepressants, Tricyclic</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>



























































<tr><td><a href="41001i715.htm">Adrenaline (epinephrine)</a></td><td class="cBV"><b>increased risk of hypertension and arrhythmias when  tricyclics given with adrenaline (epinephrine) (but local anaesthetics with adrenaline appear to be safe)</b></td><td></td></tr><tr><td><a href="41001i15.htm">Adrenergic Neurone Blockers</a></td><td> tricyclics antagonise hypotensive effect of adrenergic neurone blockers </td><td></td></tr><tr><td><a href="41001i20.htm">Alcohol</a></td><td class="cBV"><b>increased sedative effect when  tricyclics given with alcohol </b></td><td></td></tr><tr><td><a href="41001i118.htm">Amiodarone</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with amiodarone—avoid concomitant use</b></td><td>Amiodarone has a long half-life; there is a potential for drug interactions to occur for several weeks (or even months) after treatment with it has been stopped</td></tr><tr><td><a href="41001i39.htm">Anaesthetics, General</a></td><td>increased risk of arrhythmias and hypotension when  tricyclics given with general anaesthetics </td><td><i>See also</i> Surgery and Long-term Medication, 
<a title="target-block: surgery and long term med" href="6559.htm#_6559.1">section 15.1</a>



</td></tr><tr><td><a href="41001i232.htm">Antidepressants, SSRI</a></td><td class="cBV"><b>plasma concentration of some  tricyclics increased by SSRIs </b></td><td></td></tr><tr><td><a href="41001i276.htm">Antiepileptics</a></td><td class="cBV"><b> tricyclics antagonise anticonvulsant effect of antiepileptics (convulsive threshold lowered)</b></td><td></td></tr><tr><td><a href="41001i303.htm">Antihistamines</a></td><td>increased antimuscarinic and sedative effects when  tricyclics given with antihistamines </td><td>Sedative interactions apply to a lesser extent to the non-sedating antihistamines. Interactions do not generally apply to antihistamines used for topical action (including inhalation)</td></tr><tr><td><a href="41001i342.htm">Antimuscarinics</a></td><td>increased risk of antimuscarinic side-effects when  tricyclics given with antimuscarinics </td><td>Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</td></tr><tr><td><a href="41001i363.htm">Antipsychotics</a></td><td class="cBV"><b>plasma concentration of  tricyclics increased by antipsychotics—possibly increased risk of ventricular arrhythmias</b></td><td>Increased risk of toxicity with myelosuppressive drugs</td></tr><tr><td><a href="41001i404.htm">Anxiolytics and Hypnotics</a></td><td>increased sedative effect when  tricyclics given with anxiolytics and hypnotics </td><td></td></tr><tr><td><a href="41001i24.htm">Apraclonidine</a></td><td>avoidance of  tricyclics advised by manufacturer of apraclonidine </td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with atomoxetine </b></td><td></td></tr><tr><td><a href="41001i617.htm">Baclofen</a></td><td> tricyclics enhance muscle relaxant effect of baclofen </td><td></td></tr><tr><td><a href="41001i25.htm">Brimonidine</a></td><td>avoidance of  tricyclics advised by manufacturer of brimonidine </td><td></td></tr><tr><td><a href="41001i896.htm">Bupropion</a></td><td>plasma concentration of  tricyclics possibly increased by bupropion (possible increased risk of convulsions)</td><td></td></tr><tr><td><a href="41001i1189.htm">Cannabis Extract</a></td><td>possible increased risk of hypertension and tachycardia when  tricyclics given with cannabis extract </td><td></td></tr><tr><td><a href="41001i277.htm">Carbamazepine</a></td><td class="cBV"><b>metabolism of  tricyclics accelerated by carbamazepine (reduced plasma concentration and reduced effect)</b></td><td></td></tr><tr><td><a href="41001i744.htm">Cimetidine</a></td><td>plasma concentration of  tricyclics possibly increased by cimetidine </td><td></td></tr><tr><td><a href="41001i482.htm">Clonidine</a></td><td class="cBV"><b> tricyclics antagonise hypotensive effect of clonidine , also increased risk of hypertension on clonidine withdrawal</b></td><td></td></tr><tr><td><a href="41001i364.htm">Clozapine</a></td><td>possible increased antimuscarinic side-effects when  tricyclics given with clozapine </td><td>Avoid concomitant use of clozapine with drugs that have a substantial potential for causing agranulocytosis</td></tr><tr><td><a href="41001i220.htm">Coumarins</a></td><td class="cBV"><b> tricyclics may enhance or reduce anticoagulant effect of coumarins </b></td><td>Change in patient’s clinical condition, particularly associated with liver disease, intercurrent illness, or drug administration, necessitates more frequent testing. Major changes in diet (especially involving salads and vegetables) and in alcohol consumption may also affect anticoagulant control</td></tr><tr><td><a href="41001i468.htm">Diltiazem</a></td><td>plasma concentration of  tricyclics possibly increased by diltiazem </td><td></td></tr><tr><td><a href="41001i119.htm">Disopyramide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with disopyramide </b></td><td></td></tr><tr><td><a href="41001i523.htm">Disulfiram</a></td><td>metabolism of  tricyclics inhibited by disulfiram (increased plasma concentration)</td><td></td></tr><tr><td><a href="41001i524.htm">Diuretics</a></td><td>increased risk of postural hypotension when  tricyclics given with diuretics </td><td></td></tr><tr><td><a href="41001i1176.htm">Dronedarone</a></td><td class="cBV"><b>avoidance of  tricyclics advised by manufacturer of dronedarone (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i1152.htm">Droperidol</a></td><td class="cBV"><b>avoidance of  tricyclics advised by manufacturer of droperidol (risk of ventricular arrhythmias)</b></td><td></td></tr><tr><td><a href="41001i854.htm">Entacapone</a></td><td>caution with  tricyclics advised by manufacturer of entacapone </td><td></td></tr><tr><td><a href="41001i120.htm">Flecainide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with flecainide </b></td><td></td></tr><tr><td><a href="41001i1180.htm">Histamine</a></td><td> tricyclics theoretically antagonise effects of histamine—manufacturer of histamine advises avoid concomitant use</td><td></td></tr><tr><td><a href="41001i372.htm">Lithium</a></td><td>risk of toxicity when  tricyclics given with lithium </td><td></td></tr><tr><td><a href="41001i257.htm">MAOIs</a></td><td class="cBV"><b>increased risk of hypertension and CNS excitation when  tricyclics given with MAOIs , tricyclics should not be started until 2 weeks after stopping MAOIs (3 weeks if starting clomipramine or imipramine), also MAOIs should not be started for at least 1–2 weeks after stopping tricyclics (3 weeks in the case of clomipramine or imipramine)</b></td><td>For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</td></tr><tr><td><a href="41001i718.htm">Methylphenidate</a></td><td>metabolism of  tricyclics possibly inhibited by methylphenidate </td><td></td></tr><tr><td><a href="41001i262.htm">Moclobemide</a></td><td class="cBV"><b>after stopping  tricyclics do not start moclobemide for at least 1 week</b></td><td></td></tr><tr><td><a href="41001i973.htm">Moxifloxacin</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with moxifloxacin—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i615.htm">Moxonidine</a></td><td> tricyclics possibly antagonise hypotensive effect of moxonidine (manufacturer of moxonidine advises avoid concomitant use)</td><td></td></tr><tr><td><a href="41001i58.htm">Nefopam</a></td><td>side-effects possibly increased when  tricyclics given with nefopam </td><td></td></tr><tr><td><a href="41001i630.htm">Nicorandil</a></td><td> tricyclics possibly enhance hypotensive effect of nicorandil </td><td></td></tr><tr><td><a href="41001i631.htm">Nitrates</a></td><td> tricyclics reduce effects of sublingual tablets of nitrates (failure to dissolve under tongue owing to dry mouth)</td><td></td></tr><tr><td><a href="41001i711.htm">Noradrenaline (norepinephrine)</a></td><td class="cBV"><b>increased risk of hypertension and arrhythmias when  tricyclics given with noradrenaline (norepinephrine) </b></td><td></td></tr><tr><td><a href="41001i636.htm">Oestrogens</a></td><td>antidepressant effect of  tricyclics antagonised by oestrogens (but side-effects of tricyclics  possibly increased due to increased plasma concentration)</td><td>Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="4552.htm#_120026">section 7.3.1</a></td></tr><tr><td><a href="41001i85.htm">Opioid Analgesics</a></td><td>sedative effects possibly increased when  tricyclics given with opioid analgesics </td><td></td></tr><tr><td><a href="41001i808.htm">Pentamidine Isetionate</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with pentamidine isetionate </b></td><td></td></tr><tr><td><a href="41001i437.htm">Phenobarbital</a></td><td class="cBV"><b>metabolism of  tricyclics possibly accelerated by phenobarbital (reduced plasma concentration)</b></td><td></td></tr><tr><td><a href="41001i373.htm">Phenothiazines</a></td><td>increased risk of antimuscarinic side-effects when  tricyclics given with phenothiazines </td><td></td></tr><tr><td><a href="41001i284.htm">Phenytoin</a></td><td class="cBV"><b>plasma concentration of  tricyclics possibly reduced by phenytoin </b></td><td></td></tr><tr><td><a href="41001i369.htm">Pimozide</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with pimozide—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i125.htm">Propafenone</a></td><td class="cBV"><b>increased risk of arrhythmias when  tricyclics given with propafenone </b></td><td></td></tr><tr><td><a href="41001i1051.htm">Rasagiline</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tricyclics given with rasagiline </b></td><td>Rasagiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i400.htm">Ritonavir</a></td><td class="cBV"><b>plasma concentration of  tricyclics possibly increased by ritonavir </b></td><td></td></tr><tr><td><a href="41001i791.htm">Saquinavir</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with saquinavir—avoid concomitant use</b></td><td></td></tr><tr><td><a href="41001i687.htm">Selegiline</a></td><td class="cBV"><b>CNS toxicity reported when  tricyclics given with selegiline </b></td><td>Selegiline is a MAO-B inhibitor</td></tr><tr><td><a href="41001i1067.htm">Sodium Oxybate</a></td><td>increased risk of side-effects when  tricyclics given with sodium oxybate </td><td></td></tr><tr><td><a href="41001i455.htm">Sotalol</a></td><td class="cBV"><b>increased risk of ventricular arrhythmias when  tricyclics given with sotalol </b></td><td></td></tr><tr><td><a href="41001i292.htm">Terbinafine</a></td><td>plasma concentration of  tricyclics possibly increased by terbinafine </td><td></td></tr><tr><td><a href="41001i935.htm">Thyroid Hormones</a></td><td>effects of  tricyclics possibly enhanced by thyroid hormones </td><td></td></tr><tr><td><a href="41001i106.htm">Tramadol</a></td><td class="cBV"><b>increased risk of CNS toxicity when  tricyclics given with tramadol </b></td><td></td></tr><tr><td><a href="41001i467.htm">Verapamil</a></td><td>plasma concentration of  tricyclics possibly increased by verapamil </td><td></td></tr></tbody></table><p>Nortriptyline belongs to <b>Antidepressants</b>
          and will have the following interactions:
        </p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cBT" /><col width="40%" class="cBS" /><col width="30%" class="cBU" /></colgroup><tbody>


<tr><td><a href="41001i937.htm">Artemether with Lumefantrine</a></td><td class="cBV"><b>avoidance of  antidepressants advised by manufacturer of artemether/lumefantrine </b></td><td></td></tr><tr><td><a href="41001i1009.htm">Atomoxetine</a></td><td>possible increased risk of convulsions when  antidepressants given with atomoxetine </td><td></td></tr></tbody></table></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="41001i248.htm">Previous: Lofepramine</a> | <a class="top" href="41001i249.htm#">Top</a> | <a accesskey="]" href="41001i251.htm">Next: Trimipramine</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>